Understanding breast cancer through protein and molecular analysis
Official title: Breast Cancer Proteomics and Molecular Heterogeneity
Run by Cancer Trials Ireland · NCT01840293 · Data updated 2026-11-12
This study is trying to learn more about the proteins and genes in breast cancer tumors to see how they change over time and how they might affect treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1780 (estimated) |
| Sponsor | Cancer Trials Ireland Research network |
| Locations | 6 sites (Cork and 5 other locations) |
| Status | Recruiting |
| Started | February 2013 |
| Main results expected | December 2029 |
| Study ends | January 2038 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT01840293 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults diagnosed with primary breast cancer or those with suspected or confirmed recurrent/metastatic breast cancer.
✕Probably not a fit
Patients with non-breast cancer conditions or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to define the proteomic and molecular characteristics of primary and recurrent/metastatic breast tumors, focusing on the expression of specific proteins and genes such as S100, estrogen receptor, progesterone receptor, and HER2. Patients will undergo standard treatment while tissue and blood samples are collected at various time points, including pre- and post-operative stages. The study also seeks to expand knowledge on the molecular pathways involved in breast cancer progression and their response to treatments, as well as to identify potential serum markers related to cancer progression.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of breast cancer biology and better-targeted therapies for patients.
How similar studies have gone: Other studies focusing on proteomics and molecular characteristics in breast cancer have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue Or -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue Or -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue 2. Patients receiving neoadjuvant treatment are also eligible (if applicable) 3. Patients have to be ≥ 18 years of age 4. Patients must be able to give informed consent
Where it's running
-
Cork University Hospital
Cork, Ireland Recruiting -
Beaumont Hospital
Dublin, Ireland Recruiting -
St. Vincent's University Hospital
Dublin, Ireland Recruiting -
University Hospital Waterford
Waterford, Ireland Recruiting -
St James's Hospital
Dublin, Ireland Completed -
University Hospital Limerick
Limerick, Ireland Active not recruiting
Study contacts
- Study coordinator: Cancer Trials Ireland
- Email: info@cancertrials.ie
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Optimise Lung SABR: testing 3-fraction vs 5-fraction radiotherapy for peripheral NSCLC
This trial tests whether a 3-fraction SABR schedule can be as safe and effective as the standard 5-fraction schedule for patients with peripheral non-small cell lung cancer who can’t have surgery.
-
Next-generation SABR for prostate cancer across Ireland
This test uses focused high-dose stereotactic radiotherapy (SABR) with urethra-sparing, a rectal spacer, and nerve preservation for men with low-, intermediate-, or selected high-risk prostate cancer to try to control the tumor while reducing side effects.
-
Precision genomic testing for primary and metastatic breast cancer
This project will test a comprehensive genetic sequencing assay on tumour tissue to help your oncologist find targeted treatment options for adults with primary or brain-metastatic breast cancer.
-
Impact of nutritional support during chemotherapy for pancreatic cancer
This study is testing whether extra nutritional support and exercise can help people with pancreatic cancer keep their strength during chemotherapy.
-
High-dose targeted radiation for spine tumors in cancer patients
This study is testing whether a higher dose of targeted radiation given in just two sessions can help cancer patients with spine tumors who can’t have surgery feel better and control their cancer.
-
Dose-Painted Intensity Modulated Radiotherapy for Pancreatic Cancer
This study is testing a new way of giving radiation therapy to people with certain types of pancreatic cancer to see how much they can safely handle and if it helps them better than standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.